Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – What’s Next?

Shares of Bavarian Nordic (OTCMKTS:BVNRY) saw an uptick in trading volume on Tuesday . 916 shares traded hands during mid-day trading, an increase of 84% from the previous session’s volume of 498 shares.The stock last traded at $10.27 and had previously closed at $10.03.

Bavarian Nordic Stock Up 2.4%

The company has a 50 day simple moving average of $10.06 and a 200 day simple moving average of $10.93. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of 6.63 and a beta of 1.37.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings results on Friday, November 14th. The company reported $0.72 earnings per share for the quarter. Bavarian Nordic had a return on equity of 20.47% and a net margin of 35.96%.The company had revenue of $281.11 million during the quarter. As a group, analysts predict that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.